PART 3: Phenoxodiol Trials, Potential and Share price.
1. Intravenous and oral administration. When Pheno is taken by mouth then, when travelling through the gut, the Pheno molecules become coated with sugars. Unless these are removed, the drug cannot be accessed.
Only the Breast and Prostate produce enzymes which will remove this coating and hence Pheno by mouth can be taken in these 2 cases only. Intravenous injection is needed in all other cancers.
2. Type of Patient nominated for these trials: patients already having had 2 different failed treatments and in many cases only have a few months to live.
3. List of Trials. On 20 Nov. Phase II trials on 6 diferent forms of Leukemia started in the RNSH, Sydney. - Two more Phase II trials are set to start this month, one on Ovarian cancer (Yale Uni) and the other in cervical cancer. Early 2003 will see the commencement of Phase II trials for Renal cancer, Pancreatic cancer and Breast cancer (oral form); a phase I/II trial for Prostate cancer using Oral Pheno commenced Aug. 2002. All cancers except Breast and Prostate will be in the A/B mode: Trial A will use Pheno only and this will be followed by Trial B: Pheno + Cisplatin.
4. NOVOGEN develops powerful drugs: A large number of analogues of phenoxodiol have been synthesized. These are compounds based on the phenoxodiol structure, but modified to varying degrees. The effect of that structural modification is to produce new drugs with different anti- cancer effects compared to phenoxodiol. Of particular interest is the finding that it is possible to produce drugs with specific activity against specific types of cancer. This is an entirely novel and exciting finding, pointing to the ability of Novogen scientists to customize drugs for specific cancer types.
5. Potential. PART 1 discussed NV07-a and this shows much promise. The trials using Phenoxodiol will of course be most interesting. Should there be acceptable results in only a couple of diseases, then the share price could rocket. A satisfactory answer to Breast cancer alone will be sufficient.
As mentioned, lengtening of personal lives can be sufficient to attract approval from the FDA: people will live with their disease; that already happens with Prostate cancer patients.
6. Mentioning possible share prices is counter productive, particularly as the outcomes from the Trials is not certain. The Chairman of MEI, dr Kelly holds 10% of Novogen.
